Sermorelin and Ipamorelin are supplied strictly as laboratory research materials. They are not approved, intended or authorised for human consumption or any therapeutic use in this context. This article is written for qualified researchers and is not medical advice.
Two levers on the same axis
Growth hormone release is governed by more than one input, and Sermorelin and Ipamorelin pull on two of them. Sermorelin is a GHRH analogue — the synthetic equivalent of the hypothalamic signal that instructs the pituitary to produce and release GH. Ipamorelin is a GHRP, or ghrelin-mimetic, that acts through an entirely separate receptor to fire off a discrete GH pulse. They are not two versions of the same idea; they are two different classes of secretagogue, which is precisely why researchers so often place them side by side. Here is the direct comparison.
| Sermorelin | Ipamorelin | |
|---|---|---|
| Class / peptide type | GHRH analogue (GRF 1-29) | Selective GHRP / ghrelin-mimetic |
| Primary receptor | GHRH-R (pituitary) | GHS-R1a (ghrelin receptor) |
| Structure | 29 amino acids | Pentapeptide (5 aa), ~711.9 g/mol |
| Half-life | ~11 minutes | ~2 hours (IV) |
| Main research focus | GH axis / ageing biology, preserved feedback | Selective GH pulse without cortisol/prolactin rise |
| Typical pairing | Combined with a GHRP | Combined with a GHRH analogue |
| Regulatory status | Formerly FDA-approved, now withdrawn | Never approved; WADA-prohibited |
Sermorelin: the GHRH signal
Sermorelin (GRF 1-29) is a 29-amino-acid synthetic analogue of the first 29 residues of endogenous GHRH — the shortest fragment that retains full activity. It binds the GHRH receptor on pituitary somatotrophs and drives the cAMP/PKA cascade, stimulating the gland to transcribe and release its own growth hormone. Its defining research property is that it works through the pituitary rather than bypassing it: because GH is produced endogenously, somatostatin can still regulate the system, the release stays pulsatile, and the hypothalamic-pituitary negative feedback loop is preserved. That physiological restraint is what distinguishes it from exogenous recombinant GH, and it is why Sermorelin has become a reference compound in ageing-biology research, where the GHRH axis is among the first neuroendocrine systems to decline. Its half-life is short — on the order of 11 minutes — which is a large part of why longer-acting GHRH analogues exist at all. Sermorelin was previously FDA-approved for paediatric growth disorders before being commercially withdrawn. Researchers sourcing material can buy Sermorelin UK at research grade with a COA, and the full pharmacology sits on our Sermorelin knowledgebase page.
Ipamorelin: the selective GHRP pulse
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH₂, ~711.9 g/mol) developed by Novo Nordisk, and it belongs to a different class entirely. Rather than mimicking GHRH, it is a selective agonist of the GHS-R1a ghrelin receptor. Binding activates phospholipase C and mobilises intracellular calcium in somatotrophs, producing a discrete, time-limited GH pulse; it also suppresses somatostatin at the hypothalamic level, so it acts on both the stimulatory and inhibitory arms of GH control. What made Ipamorelin notable was its selectivity: unlike earlier GHRPs such as GHRP-6 and GHRP-2, which reliably raised cortisol and ACTH, Ipamorelin produces a comparable GH response without meaningful co-stimulation of cortisol, prolactin, ACTH or the other pituitary hormones — even at doses far above its GH-releasing threshold. That makes it valuable wherever a clean, isolated GH signal is needed without adrenocortical confounders. Its half-life is longer than Sermorelin's, around two hours (IV). It has never been approved for any therapeutic indication and is prohibited under WADA's peptide-hormone category. Material is available to buy Ipamorelin UK, with the receptor detail on the Ipamorelin knowledgebase page.
What the differences mean in a research context
The cleanest way to read this comparison is by pathway. Sermorelin engages the GHRH receptor; Ipamorelin engages the ghrelin receptor (GHS-R1a). Because these are two distinct receptors driving the same downstream output, the two compounds are complementary rather than strictly either/or — a point our source literature makes directly, where co-administration of a GHRH analogue with a GHS-R agonist produced a substantially greater GH response than either compound alone. That synergy is the whole reason the two classes are studied together: one primes the pituitary to produce GH, the other triggers the pulse and lifts somatostatin's brake.
The mechanisms also differ in character. Sermorelin's contribution is physiological restraint — endogenous production, preserved feedback, a very short half-life that keeps exposure tightly episodic. Ipamorelin's contribution is selectivity — a robust GH pulse uncoupled from cortisol and prolactin, which removes a common confounder from experimental designs. Their pharmacokinetics reflect this too: Sermorelin's ~11-minute half-life gives a sharp, transient signal, while Ipamorelin's ~2-hour half-life sustains its window somewhat longer.
Regulatory footing separates them as well. Sermorelin carries a mature history as a formerly FDA-approved compound, since withdrawn; Ipamorelin was never approved and sits on the WADA Prohibited List. For a researcher, the takeaway is not that one is "better" but that they answer different questions — and frequently the same protocol wants both. Note this is a distinct pairing from our CJC-1295 vs Ipamorelin comparison; here the GHRH side is Sermorelin specifically, with its shorter half-life and preserved-feedback profile.
The bottom line
Sermorelin is the GHRH signal — it tells the pituitary to make growth hormone and keeps the body's own feedback in charge. Ipamorelin is the selective GHRP — it fires a clean GH pulse through the ghrelin receptor without the cortisol and prolactin baggage of older GHRPs. GHRH versus GHRP, complementary by design. For research-grade material, see our dedicated pages to buy Sermorelin UK and buy Ipamorelin UK, each ≥99% purity with a COA.